- Report
- October 2023
- 123 Pages
From €3039EUR$3,450USD£2,671GBP
- Report
- April 2023
- 115 Pages
Global
From €4184EUR$4,750USD£3,677GBP
- Report
- October 2024
- 128 Pages
United States
From €3039EUR$3,450USD£2,671GBP
- Report
- May 2024
- 185 Pages
Global
From €3963EUR$4,500USD£3,484GBP
- Report
- September 2023
- 75 Pages
Global
From €3519EUR$3,995USD£3,093GBP
- Report
- October 2023
Global
From €3171EUR$3,600USD£2,787GBP
- Report
- October 2023
Africa, Middle East
From €1321EUR$1,500USD£1,161GBP
- Report
- October 2023
North America
From €1321EUR$1,500USD£1,161GBP
- Book
- October 2020
Asia Pacific

Congenital heart defects (CHD) are structural abnormalities of the heart that are present at birth. They are the most common type of birth defect, affecting approximately 1 in 100 newborns. CHD can range from mild to severe, and can involve the heart's walls, valves, or blood vessels. Treatment for CHD can include medications, surgery, or a combination of both.
The Congenital Heart Defect market within the context of Cardiology is a rapidly growing field. Advances in medical technology have enabled earlier diagnosis and improved treatment options for CHD. This has led to increased demand for medical devices and services related to CHD. Additionally, the increasing prevalence of CHD has driven the need for better patient care and improved outcomes.
Companies in the Congenital Heart Defect market include Boston Scientific, Medtronic, Abbott, Edwards Lifesciences, and St. Jude Medical. These companies provide a range of products and services related to CHD, including medical devices, diagnostics, and treatments. Show Less Read more